Skip to Main Content
Recruiting

PEPN2415: AZD1390 for High-Grade Gliomas

About this study

High-grade glioma, diffuse midline glioma, and diffuse intrinsic pontine glioma are serious, hard to treat brain tumors in children and teens. These tumors grow quickly. They do not respond well to current medicines and treatments. Doctors need new medicines that can help make treatments like radiation therapy work better.

ATM is a protein that cancer cells use to protect themselves from treatments like radiation or chemotherapy. AZD1390 is a new drug that blocks ATM. When ATM is blocked, cancer cells cannot fix their damaged parts after treatment. This makes the cancer cells more likely to die, and it helps radiation work better.

It is not yet known how safe AZD1390 is or what the best dose might be for young patients. This study will help find the right dose and check for side effects, making sure the treatment is as safe as possible.

In this study, doctors will give different amounts of AZD1390 to patients to find the safest dose. They will watch closely for any side effects and see how the body handles the medicine. The study will also check if the combination of AZD1390 and radiation helps shrink the tumors or stop them from growing.

This research is important because it may lead to better treatments for children with high-grade gliomas, diffuse midline gliomas, and diffuse intrinsic pontine gliomas. By finding a safe and effective way to use AZD1390 with radiation therapy, doctors hope to improve outcomes for patients with these brain tumors.

Eligibility overview

  • High-grade glioma, diffuse midline glioma (non-pontine)
  • Diffuse intrinsic pontine glioma will be available in the future
  • 1–22 years old 

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Overview

Full title:

PEPN2415: A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD1390 When Combined with Focal Radiation in Pediatric Patients with High-Grade Glioma

Study goal:

To study AZD1390 combined with radiation therapy for treating pediatric high-grade glioma.

Age:

1–22 years old

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.

 

Learn more